Arrowhead Pharmaceuticals Stock Performance
| ARWR Stock | USD 63.69 0.13 0.20% |
Arrowhead Pharmaceuticals holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.63, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arrowhead Pharmaceuticals will likely underperform. Use Arrowhead Pharmaceuticals value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Arrowhead Pharmaceuticals.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Arrowhead Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Arrowhead Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.20) | Five Day Return 3.18 | Year To Date Return (6.05) | Ten Year Return 1.5 K | All Time Return (97.82) |
Last Split Factor 1:10 | Last Split Date 2011-11-17 |
1 | Acquisition by Christopher Anzalone of 180000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 12/12/2025 |
2 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635 | 12/15/2025 |
3 | Disposition of 3221 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 67.87 subject to Rule 16b-3 | 12/16/2025 |
4 | Disposition of 16545 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 6.15 subject to Rule 16b-3 | 12/29/2025 |
5 | Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome | 01/05/2026 |
6 | Acquisition by Christopher Anzalone of 340000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 01/14/2026 |
7 | Arrowhead Pharmaceuticals Valuation Check After Redemplos Third Regulatory Approval And Optimistic Pipeline Outlook | 01/26/2026 |
8 | Strs Ohio Grows Position in Arrowhead Pharmaceuticals, Inc. ARWR | 02/02/2026 |
9 | Arrowhead Stock Has Skyrocketed 290 percent in One Year, and One Fund Trimmed Its Holdings by 4 Million | 02/03/2026 |
10 | Ciena Set to Join SP 500 Arrowhead Pharmaceuticals to Join SP MidCap 400 ADT and OneSpaWorld Holdings to Join SP SmallCap 600 | 02/04/2026 |
11 | Arrowhead Pharmaceuticals Issues Quarterly Earnings Results | 02/06/2026 |
12 | Disposition of 560 shares by Obrien Patrick of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 02/09/2026 |
13 | Arrowhead Joins SP 400 As Profitability Shifts Investor Focus | 02/11/2026 |
14 | Disposition of 8416 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 60.51 subject to Rule 16b-3 | 02/13/2026 |
15 | Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech MA | 02/17/2026 |
| Begin Period Cash Flow | 102.7 M | |
| Total Cashflows From Investing Activities | -129.3 M |
Arrowhead | Build AI portfolio with Arrowhead Stock |
Arrowhead Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,809 in Arrowhead Pharmaceuticals on November 20, 2025 and sell it today you would earn a total of 2,560 from holding Arrowhead Pharmaceuticals or generate 67.21% return on investment over 90 days. Arrowhead Pharmaceuticals is currently generating 1.001% in daily expected returns and assumes 5.2049% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Arrowhead, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arrowhead Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Arrowhead Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 63.69 | 90 days | 63.69 | about 42.8 |
Based on a normal probability distribution, the odds of Arrowhead Pharmaceuticals to move above the current price in 90 days from now is about 42.8 (This Arrowhead Pharmaceuticals probability density function shows the probability of Arrowhead Stock to fall within a particular range of prices over 90 days) .
Arrowhead Pharmaceuticals Price Density |
| Price |
Predictive Modules for Arrowhead Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arrowhead Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arrowhead Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arrowhead Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Arrowhead Pharmaceuticals is not an exception. The market had few large corrections towards the Arrowhead Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arrowhead Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arrowhead Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.69 | |
β | Beta against Dow Jones | 1.63 | |
σ | Overall volatility | 9.97 | |
Ir | Information ratio | 0.14 |
Arrowhead Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arrowhead Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arrowhead Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Arrowhead Pharmaceuticals is way too risky over 90 days horizon | |
| Arrowhead Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Arrowhead Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech MA |
Arrowhead Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arrowhead Stock often depends not only on the future outlook of the current and potential Arrowhead Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arrowhead Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 133.8 M | |
| Cash And Short Term Investments | 919.4 M |
Arrowhead Pharmaceuticals Fundamentals Growth
Arrowhead Stock prices reflect investors' perceptions of the future prospects and financial health of Arrowhead Pharmaceuticals, and Arrowhead Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arrowhead Stock performance.
| Return On Equity | 0.76 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 8.33 B | ||||
| Shares Outstanding | 140.03 M | ||||
| Price To Earning | 482.39 X | ||||
| Price To Book | 15.73 X | ||||
| Price To Sales | 8.17 X | ||||
| Revenue | 829.45 M | ||||
| Gross Profit | 1.09 B | ||||
| EBITDA | 164.82 M | ||||
| Net Income | 30.11 M | ||||
| Cash And Equivalents | 416.5 M | ||||
| Cash Per Share | 3.93 X | ||||
| Total Debt | 366.28 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 3.37 X | ||||
| Book Value Per Share | 4.14 X | ||||
| Cash Flow From Operations | 179.55 M | ||||
| Earnings Per Share | 1.60 X | ||||
| Market Capitalization | 8.92 B | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (1.63 B) | ||||
| Working Capital | 755.15 M | ||||
| Current Asset | 90.5 M | ||||
| Current Liabilities | 25.64 M | ||||
About Arrowhead Pharmaceuticals Performance
Assessing Arrowhead Pharmaceuticals' fundamental ratios provides investors with valuable insights into Arrowhead Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arrowhead Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.1 K | 51.6 K | |
| Return On Capital Employed | 0.10 | 0.10 |
Things to note about Arrowhead Pharmaceuticals performance evaluation
Checking the ongoing alerts about Arrowhead Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arrowhead Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arrowhead Pharmaceuticals is way too risky over 90 days horizon | |
| Arrowhead Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Arrowhead Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech MA |
- Analyzing Arrowhead Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arrowhead Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Arrowhead Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arrowhead Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arrowhead Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arrowhead Pharmaceuticals' stock. These opinions can provide insight into Arrowhead Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.